Gantenerumab is a medication being studied for its potential to slow down the progression of Alzheimer’s disease. It works by targeting and removing amyloid plaques in the brain, which are believed to contribute to the symptoms and progression of Alzheimer’s disease.

Solanezumab is another investigational drug in the trial, designed to bind to amyloid-beta proteins in the brain. By doing so, it aims to prevent these proteins from forming plaques, which are associated with the development and progression of Alzheimer’s disease.

DIAN-TU-001 is a code name for a study drug being tested in this trial. It is being evaluated for its ability to modify the disease process in individuals with a genetic mutation that causes Alzheimer’s disease. The goal is to see if it can slow down cognitive decline or improve biomarkers related to the disease.

Dominantly Inherited Alzheimer Disease (DIAD) – This is a rare form of Alzheimer’s disease that is passed down through families in an autosomal dominant manner, meaning that inheriting just one copy of the mutated gene from an affected parent can cause the disease. It typically begins at a younger age than the more common sporadic form of Alzheimer’s, often in a person’s 30s to 50s. The disease progresses with the gradual decline in memory, thinking, and reasoning skills. As it advances, individuals may experience confusion, mood changes, and difficulty with language and movement. Over time, the ability to perform daily activities becomes increasingly impaired. The progression of symptoms can vary, but it generally follows a similar pattern to other forms of Alzheimer’s disease.